Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Eosinophilia associated with clozapine - A case report
Publication

Publications

Eosinophilia associated with clozapine - A case report

Title
Eosinophilia associated with clozapine - A case report
Type
Other Publications
Year
2017
Authors
Abreu, T
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Carvalho, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Von Doellinger, O
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Other information
Authenticus ID: P-00R-BHF
Abstract (EN): <jats:sec id="S0924933800215708_abst0001" sec-type="other"><jats:title>Objectives</jats:title><jats:p>Clozapine is an atypical anti-psychotic used in the treatment of schizophrenia and other psychotic disorders. It is associated with several side effects, namely, hematologic disorders, the more common being agranulocytosis. Some cases of eosinophilia have been described. This work describes a case of transient eosinophilia caused by clozapine.</jats:p></jats:sec><jats:sec id="S0924933800215708_abst0002" sec-type="methods"><jats:title>Methods</jats:title><jats:p>Description of a clinical case.</jats:p></jats:sec><jats:sec id="S0924933800215708_abst0003" sec-type="results"><jats:title>Results</jats:title><jats:p>A 22-year-old female patient, with a treatment resistant psychotic disorder initiated clozapine in a slow titration to 300 mg. Ten days after initiating clozapine, the patient presented with eosinophilia (started with 6.6 × 108/L and peaked at 10.0 × 108/L). Two weeks later, the patient presented with a skin rash in the arms and legs. The case was discussed with internal medicine service and other causes of eosinophilia were excluded. Since the eosinophilia was mild, the rash was not severe and the patient did not present any other symptoms or signs, it was not considered necessary to stop clozapine. During the next three months, with close monitoring, the eosinophilia and the skin rash slowly resolved.</jats:p></jats:sec><jats:sec id="S0924933800215708_abst0004" sec-type="conclusions"><jats:title>Conclusions</jats:title><jats:p>This is a case of a patient who presented mild eosinophilia and skin rash, associated to clozapine, with spontaneous resolution. We draw attention to the need of close monitorization and exclusion of other causes of eosiniphilia and rash. Furthermore, other hematologic disorders should be considered besides agranulocytosis, namely eosinophilia, when prescribing clozapine.</jats:p></jats:sec><jats:sec id="S0924933800215708_abst0005" sec-type="other"><jats:title>Disclosure of interest</jats:title><jats:p>The authors have not supplied their declaration of competing interest.</jats:p></jats:sec>
Language: English
Type (Professor's evaluation): Scientific
Documents
We could not find any documents associated to the publication.
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-31 at 15:57:17 | Privacy Policy | Personal Data Protection Policy | Whistleblowing